Identification and study of the vascular disease gene at 9p21.3
9p21.3血管疾病基因的鉴定与研究
基本信息
- 批准号:8467030
- 负责人:
- 金额:$ 58.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-15 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): As much as half of the risk for atherosclerotic coronary heart disease (CHD) is genetic in nature, and an unprecedented amount of resources have recently been directed at association-based studies employing high density genome-wide scanning to identify genetic variation associated with CHD. These studies have identified a single region of the genome as the most highly associated with disease in an intergenic segment of chromosome 9 at p21.3, the Chromosome 9p21.3 CHD-Associated Region (C9CAR). The attributable risk for CHD explained by variation in this locus has been estimated at 10-15%. In addition to CHD, variants at C9CAR have been associated with other vascular diseases, including abdominal aortic aneurysm, stroke, and peripheral vascular disease. Although additional human genetics mapping efforts are underway in this laboratory and others, it is unlikely that they will identify the causative variation or elucidate the biology underlying the risk associated with 9p21.3 variants. Further progress will require efforts with basic molecular biology and animal model approaches. While there are several genes in this region of 9p21.3, none have been clearly linked to the disease-associated variation, and the causative variation has not been defined. Compelling recent evidence now suggests that a cyclin-dependent kinase inhibitor gene, CDKN2B, and a non-coding antisense RNA in the CDKN2B locus named ANRIL, are the most likely candidate genes linked to the variation at 9p21.3. Studies proposed here will identify which of these two candidates is the related gene, the mechanism by which 9p21.3 variation alters the function of this gene, and the fundamental disease-related pathways that it in turn regulates. Experiments in Specific Aim 1 will investigate allelic expression imbalance between the alleles of CDKN2B and ANRIL, and link this imbalance to variation in these genes as well as the intergenic C9CAR region. These studies will identify the causative gene and localize cis-acting transcriptional regulatory sequences. Additional experiments in this aim will characterize putative enhancer elements at C9CAR, identify the transcription factors that bind these elements and provide insights into cell types and signaling pathways that mediate the risk associated with this region. Specific Aim 2 will employ targeted deletion of CDKN2B and other genes at 9p21.3 in the apoE null atherosclerosis mouse model to provide insights into the cellular and molecular aspects of disease risk. Finally, in Specific Aim 3, targeted in vitro studies will further investigate how CDKN2B or ANRIL regulate basic cell fate decisions in vascular cell types and contribute to atherosclerotic disease. This work will identify the causative gene at 9p21.3, and disease related upstream and downstream pathways for further study and therapeutic targeting.
描述(由申请人提供):动脉粥样硬化冠心病(CHD)的风险多达一半本质上是遗传性的,并且最近已经针对基于关联的研究进行了前所未有的资源,该研究采用高密度范围的范围扫描来鉴定与CHD相关的遗传变异。这些研究已将基因组的单个区域确定为在P21.3染色体9 P21.3(染色体9P21.3 CHD相关区域(C9CAR))的基因间段(C9CAR)中。该基因座的变化解释的CHD的归因风险估计为10-15%。除冠心病外,C9CAR的变体还与其他血管疾病有关,包括腹部主动脉瘤,中风和周围血管疾病。尽管该实验室和其他实验室正在进行其他人类遗传学映射工作,但他们不太可能识别出病因变异或阐明与9p21.3变体相关的风险的生物学。进一步的进步将需要基本分子生物学和动物模型方法的努力。尽管在9p21.3的该区域中有几个基因,但没有与疾病相关的变异明确关联,并且尚未定义病因变异。现在,令人信服的最近证据表明,在CDKN2B基因座中,依赖细胞周期蛋白的激酶抑制剂基因CDKN2B和名为Anril的非编码反义RNA是与9p21.3变异有关的最有可能的候选基因。 这里提出的研究将确定这两个候选者中的哪一个是相关基因,即9p21.3变异改变该基因的功能的机制,以及其基本与疾病相关的途径,进而调节。特定目标1中的实验将研究CDKN2B和Anril等位基因之间的等位基因表达不平衡,并将这种不平衡与这些基因的变异以及基因间C9CAR区域联系起来。这些研究将确定因果基因并定位顺序的转录调节序列。此目标中的其他实验将表征C9CAR处的推定增强子元素,确定结合这些元素的转录因子,并提供有关介导与该区域相关风险的细胞类型和信号通路的见解。特定的目标2将在APOE无动脉粥样硬化小鼠模型中采用9P21.3的CDKN2B和其他基因的靶向缺失,以洞悉疾病风险的细胞和分子方面。最后,在特定的目标3中,有针对性的体外研究将进一步研究CDKN2B或Anril如何调节血管细胞类型中的基本细胞命运决策,并导致动脉粥样硬化疾病。这项工作将在9p21.3处确定病因基因,以及与疾病相关的上游和下游途径,以进一步研究和治疗靶向。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Study of exonic variation identifies incremental information regarding lipid-related and coronary heart disease genes.
外显子变异的研究确定了有关脂质相关和冠心病基因的增量信息。
- DOI:10.1161/circresaha.114.304693
- 发表时间:2014
- 期刊:
- 影响因子:20.1
- 作者:Assimes,ThemistoclesL;Quertermous,Thomas
- 通讯作者:Quertermous,Thomas
共 1 条
- 1
THOMAS QUERTERMOU...的其他基金
Molecular mechanisms of vascular calcification and their connection to coronary disease risk
血管钙化的分子机制及其与冠心病风险的关系
- 批准号:1067374210673742
- 财政年份:2022
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
Elucidating Genotype-Phenotype Relationship of Polygenic Dilated Cardiomyopathies: Administrative Supplement (INCLUDE)
阐明多基因扩张型心肌病的基因型-表型关系:行政补充(包括)
- 批准号:1040472310404723
- 财政年份:2021
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
Identifying tobacco-genetic interactions through study of the aryl hydrocarbon receptor pathway.
通过研究芳基碳氢化合物受体途径来识别烟草与遗传的相互作用。
- 批准号:1020711210207112
- 财政年份:2021
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
Identifying tobacco-genetic interactions through study of the aryl hydrocarbon receptor pathway.
通过研究芳基碳氢化合物受体途径来识别烟草与遗传的相互作用。
- 批准号:1037214710372147
- 财政年份:2021
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
PDGFD regulates a transcriptional network to modulate smooth muscle cell transition and coronary artery disease risk
PDGFD 调节转录网络以调节平滑肌细胞转变和冠状动脉疾病风险
- 批准号:1059393410593934
- 财政年份:2021
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
Identifying tobacco-genetic interactions through study of the aryl hydrocarbon receptor pathway.
通过研究芳基碳氢化合物受体途径来识别烟草与遗传的相互作用。
- 批准号:1059159710591597
- 财政年份:2021
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
PDGFD regulates a transcriptional network to modulate smooth muscle cell transition and coronary artery disease risk
PDGFD 调节转录网络以调节平滑肌细胞转变和冠状动脉疾病风险
- 批准号:1017266610172666
- 财政年份:2021
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
PDGFD regulates a transcriptional network to modulate smooth muscle cell transition and coronary artery disease risk
PDGFD 调节转录网络以调节平滑肌细胞转变和冠状动脉疾病风险
- 批准号:1038575310385753
- 财政年份:2021
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
Single Cell Sequencing of Human iPSC-CM Subtype Identity and Function
人类 iPSC-CM 亚型身份和功能的单细胞测序
- 批准号:97639169763916
- 财政年份:2019
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
LncRNA Transcriptional Mechanisms of Coronary Artery Disease Risk
冠状动脉疾病风险的 LncRNA 转录机制
- 批准号:1032764110327641
- 财政年份:2019
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
相似国自然基金
染色体9p21.3区域遗传变异与体细胞突变在食管鳞癌发生中的作用及其生物学机制研究
- 批准号:81572421
- 批准年份:2015
- 资助金额:57.0 万元
- 项目类别:面上项目
5p15.33、7p11.2、8q24.21、9p21.3、11q23.3和20q13.33座位遗传多态与胶质母细胞瘤放疗后生存的关系研究
- 批准号:81372417
- 批准年份:2013
- 资助金额:16.0 万元
- 项目类别:面上项目
相似海外基金
Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment
9p21.3 缺失肿瘤微环境中的靶向蛋白精氨酸甲基化
- 批准号:489995489995
- 财政年份:2023
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:Operating GrantsOperating Grants
Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment
9p21.3 缺失肿瘤微环境中的靶向蛋白精氨酸甲基化
- 批准号:498862498862
- 财政年份:2023
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:Operating GrantsOperating Grants
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
肾细胞癌有效抗肿瘤免疫的肿瘤和免疫决定因素
- 批准号:1063890710638907
- 财政年份:2023
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
Comprehensive functional genomic analysis of the multi-disease associated CDKN2A/B locus
多种疾病相关 CDKN2A/B 基因座的综合功能基因组分析
- 批准号:1067297510672975
- 财政年份:2021
- 资助金额:$ 58.85万$ 58.85万
- 项目类别:
Functional Characterization of Glioma GWAS Variants
胶质瘤 GWAS 变异体的功能表征
- 批准号:91596869159686
- 财政年份:2016
- 资助金额:$ 58.85万$ 58.85万
- 项目类别: